BeiGene
ONC
#682
Rank
โ‚น2.483 T
Marketcap
โ‚น21,884
Share price
2.82%
Change (1 day)
82.20%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeiGene (ONC)

Earnings in 2024 (TTM): -โ‚น47.61 Billion

According to BeiGene 's latest financial reports the company's current earnings are โ‚น3.81 Billion. , an increase over its 2023 earnings that were of -โ‚น103.18 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeiGene from 2015 to 2024

Annual earnings

Year Earnings Change
2024 -โ‚น48.55 Billion-52.95%
2023 -โ‚น103.18 Billion-32.52%
2022 -โ‚น152.9 Billion24.39%
2021 -โ‚น122.92 Billion-13.21%
2020 -โ‚น141.62 Billion72.69%
2019 -โ‚น82.01 Billion36.01%
2018 -โ‚น60.3 Billion616.83%
2017 -โ‚น8.42 Billion-15.24%
2016 -โ‚น9.93 Billion107.91%
2015 -โ‚น4.78 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-โ‚น1.56 Billion-96.80%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น0.89 Billion-98.18%๐Ÿ‡บ๐Ÿ‡ธ USA